StockDriftsStockDriftsTop 39 Atle Fund Management AB Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 9.62% | 29.8K | $35.8M | -24.93%(-9.90K) | $773.22(+52.53%) | 2026-06-30 | |
| MRK | MERCK & CO. INC | 6.55% | 189.4K | $24.3M | +459.35%(+155.50K) | $119.75(+13.75%) | 2026-06-30 | |
| JNJ | JOHNSON & JOHNSON | 5.84% | 85.4K | $21.7M | -7.53%(-6.95K) | $225.69(+15.40%) | 2026-06-30 | |
| ABBV | ABBVIE INC | 4.35% | 64.3K | $16.2M | -40.54%(-43.86K) | $185.73(+34.29%) | 2026-06-30 | |
| CVS | CVS HEALTH CORP | 4.07% | 146.1K | $15.1M | +514.57%(+122.33K) | $85.26(+13.95%) | 2026-06-30 | |
| TMO | THERMO FISHER SCIENTIFIC CORP | 3.76% | 27.9K | $14.0M | +21.20%(+4.87K) | $523.27(+12.79%) | 2026-06-30 | |
| RVMD | REVOLUTION MEDICINES INC | 3.68% | 73.1K | $13.7M | -88.16%(-544.17K) | $81.84(+162.29%) | 2026-06-30 | |
| BIIB | BIOGEN INC | 3.65% | 62.8K | $13.6M | new | $201.82(+3.97%) | 2026-06-30 | |
| NBIX | NEUROCRINE BIOSCIENCES INC | 3.31% | 72.9K | $12.3M | -18.72%(-16.79K) | $127.31(+19.96%) | 2026-06-30 | |
| MIRM | MIRUM PHARMACEUTICALS INC | 3.17% | 100.8K | $11.8M | -48.51%(-94.96K) | $63.03(+59.67%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | +15.27% | +53.17% | +12.07% | +76.79% |
| Top 20 Holdings Unweighted | +15.80% | +55.30% | +10.78% | +66.87% |
Atle Fund Management AB reports $371.70M in US-listed equity holdings across 39 positions in its most recent 13F filing. Its largest disclosed positions are LLY (9.6%), MRK (6.5%) and JNJ (5.8%). The top 20 holdings account for 74.19% of reported assets. Its disclosed equity book has returned +53.17% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Atle Fund Management AB, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Atle Fund Management AB’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1381843). View Atle Fund Management AB’s 13F filings on SEC